Form D · Biotechnology

Cardurion Pharmaceuticals, Inc.

Burlington, MA · CIK 0001702453

Offering snapshot reported Jul 24, 2024 · SEC filing

Reported sold
$260M
Offering amount: $260M
Investors reported
19
Form D · investor count
Minimum accepted
$0
Reported outside-investor minimum
First sale
Jul 10, 2024
As reported in this filing

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Jul 24, 2024Initial$260,410,720No comparison19SEC filing
Jul 14, 2023Amendment$128,125,000$82,000,000vs Nov 3, 20212SEC filing
Dec 30, 2022Initial$17,500,000No comparison2SEC filing
Nov 3, 2021Initial$46,125,000No comparison2SEC filing
Nov 20, 2019Initial$10,000,000No comparison2SEC filing
Apr 4, 2017Initial$15,650,000No comparison1SEC filing

Offering details

Securities
Equity
Exemptions
06b
Duration over one year
No
Business combination
No
Sales commissions
$0
Finders' fees
$0
Form D file number
021-519629

Source: Form D, filed Jul 24, 2024. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Nicholas Downing Director
Keith Gottesdiener Director
Jeb Keiper Director
Adam Koppel Director
Peter Lawrence Director, Executive
Daniel Lynch Director
Edward Mathers Director
Michael Mendelsohn Director, Executive
Kenneth Novack Director
Evan Rachlin Director
Emma Reeve Director
Amy Schulman Director

Issuer details

Industry: Biotechnology (See others in industry)

Address:
78 Blanchard Road, Suite 200
Burlington, MA, 01803